ÌÇÐÄVlog

Scott M. Bradfield, MD

Physician

¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· Children's Health, Jacksonville 807 Children's Way Jacksonville, FL 32207

Fellowship

  • Pediatric Hematology/Oncology - Seattle Children's Hospital, 2003

Residency

  • Pediatrics - Massachusetts General Hospital/ Harvard Med School, 2000

Education

  • M.D. - University of South Florida, 1997

Board Certifications

  • American Board of Pediatrics/Hematology-Oncology
  • American Board of Pediatrics/General Pediatrics

  • Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: An Update of the University of Florida Experience.; International journal of radiation oncology, biology, physics; (2022).

  • Modern Therapy for Chest Wall Ewing Sarcoma: An Update of the University of Florida Experience.; International journal of radiation oncology, biology, physics; (2022).

  • A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors; Child's Nervous System; (2022).

  • SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology; (2021).

  • Proton radiotherapy for infant rhabdomyosarcoma: Rethinking young age as an adverse prognostic factor.; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology; (2021).

  • Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma.; International journal of radiation oncology, biology, physics; (2020).

  • Treatment Outcomes After Proton Therapy for Ewing Sarcoma of the Pelvis.; International journal of radiation oncology, biology, physics; (2020).

  • Pleuropulmonary blastoma-like peritoneal sarcoma: a newly described malignancy associated with biallelic DICER1 pathogenic variation.; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc; (2020).

  • Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base.; Pediatric blood & cancer; (2019).

  • 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.; Acta oncologica (Stockholm, Sweden); (2019).

  • Intravenous and Oral Posaconazole Pharmacokinetics in a Five-Year-Old With Mucor: A Case Report and Review of the Literature.; The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG; (2019).

  • Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax.; Pediatric blood & cancer; (2018).

  • False Lung Metastasis: Concurrent Ewing Sarcoma and Minimally Invasive Adenocarcinoma.; Journal of pediatric hematology/oncology; (2018).

  • Eliciting parental values and preferences in the medical decision-making process.; The American journal of bioethics : AJOB; (2015).

  • Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer.; Pediatric blood & cancer; (2014).

  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.; Antimicrobial agents and chemotherapy; (2011).

  • When is state intervention justified? An ethics consult gone bad.; Pediatric blood & cancer; (2010).

  • "STOP"-ping harm: when is state intervention justified?; Pediatric blood & cancer; (2010).

  • Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.; Pediatric blood & cancer; (2006).

  • Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.; Cancer; (2004).

  • Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection.; Leukemia; (2004).

  • Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.; Journal of pediatric hematology/oncology; (2003).